Rafael Holdings is a biotechnology company advancing clinical-stage pharmaceutical candidates and maintaining a diversified portfolio of investments in related biotech and medical device companies. Its lead asset is Trappsol® Cyclo™, a cyclodextrin-based compound in Phase 3 trials for Niemann-Pick Disease Type C1, a rare genetic disorder; the company also owns controlling stakes in subsidiaries developing cancer therapeutics, orthopedic devices, and technology platforms to enhance product bioavailability. Rafael generates potential value through the advancement of these pipeline programs toward regulatory approval and commercialization, supported by portfolio company licensing partnerships, collaborative arrangements, and milestone-based funding, while holding a leased office facility in Israel.